Insulin Glulisine, Recombinant

Modality

Insulin Glulisine, Recombinant

Description of Insulin Glulisine, Recombinant

Insulin glulisine, chemically named Lys(B3), Glu(B29) human insulin analog, is a rapid-acting human insulin variant. Insulin glulisine (Apidra) was developed by Sanofi, and first approved in 2004 for glycemic control in diabetes mellitus patients.

Synonyms

Apidra, HMR 1964, insulin glulisine (genetical recombination), insulin glulisine (recombinant DNA origin), アピドラ, 艾倍得

Amino Acid Sequence of Insulin Glulisine

Insulin glulisine differs from native human insulin at two amino acids of the B chain, chemically named Lys(B3), Glu(B29) human insulin analog.

Fig 1. Structure formula of insulin glulisine

Expression System of Insulin Glulisine

Brand Name	Active Substance	Expression System
Apidra	Insulin glulisine	Bacteria (Escherichia coli)

Formulation of Insulin Glulisine

Inactive ingredients (Excipients) in Apidra (Vial, Prefilled Cartridge)

Metacresol, polysorbate 20 (PS20), sodium chloride, tromethamine, and hydrochloric acid or sodium hydroxide (pH 7.3).

All Categories

Insulin Glulisine, Recombinant

Modality